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Multiple sclerosis is an incurable, debilitating, nervous system disease, 
which causes are largely unknown, and which affects hundreds of thou-
sands of people across the United States. Early research suggests the 
impact that psychological factors can have on a patient's physical and 
mental health status. Self-efficacy, the belief in one's ability to cope with 
a situation, has been found to offer beneficial and protective effects in 
patients suffering from conditions such as rheumatoid arthritis, sickle cell 
disease, and fibromylagia. This comprehensive literature review sought to 
look at psychological research that has considered the relationship be-
tween self-efficacy and health promoting behaviors, symptom and overall 
illness severity, mental health status, and perceived quality of life in 
people suffering from multiple sclerosis. The literature strongly supports 
a relationship between self-efficacy and health promoting behaviors. The 
literature was ambiguous as to a relationship between self-efficacy and 
illness severity—with some studies finding a significant relationship and 
others not. The literature reviewed also suggests a potential relationship 
between self-efficacy and other cognitive components such as mental 
health status, mood control, and self-esteem. The literature supports a 
relationship between self-efficacy and perceived quality of life. 
Multiple Sclerosis is an incurable, 
chronic, debilitating neurological disease that 
affects the central nervous system. It is caused 
by a destruction and subsequent reduction of 
myelin, which acts as a conductor of electrical 
impulses, facilitating the transfer of information  
between nerves, and also as an insulator, protect-
ing the nerves themselves (About MS). This 
demyelination slows the transfer of information 
from nerve to nerve and leaves the nerve vulner-
able to inflammation and damage, as well as 
disrupts the smooth transfer of impulses, leading 
12 
to problems with "vision, strength, sensation, 
and coordination" (Shnek et al., 1997, p.187). 
Many of the symptoms of multiple sclerosis are 
in fact caused by this disruption of the flow of 
nerve impulses (Schapiro, 1991, as cited in 
Stuifbergen, Seraphine, & Roberts, 2000). These 
symptoms include cognitive disturbances, such 
as memory, attention, and problem-solving 
difficulties, walking difficulties (About MS), 
weakness, numbness, fatigue, visual distur-
bances, dizziness, problems maintaining one's 
balance, loss of coordination, bladder and bowel 
problems, changes in sexual functioning, pain, 
and spasticity. 
About 400,000 individuals are currently 
diagnosed with MS in the United States, and 
there are about 10,000 newly diagnosed cases 
each year (Fraser, Hadjimichael, & Vollmer, 
2001). Worldwide, it is estimated that 2.5 
million individuals have the disease (About MS). 
MS is twice more prevalent in women than in 
men, and is most common in whites, especially 
people with a Northern European background 
(About MS). The general age of onset is between 
the ages of 20 and 40 (Barnwell & Kavanagh, 
1997). 
There are two categories of MS: relaps-
ing-remitting MS and progressive MS. The 
relapsing-remitting type, the most common form, 
is characterized by almost complete recovery 
between exacerbations. However, exacerbations 
often get progressively worse and can involve 
intense neurological dysfunction (Barnwell & 
Kavanagh, 1997). Progressive forms of MS, 
which are much less common, include primary 
progressive MS, progressive-relapsing MS, and 
secondary progressive MS. These forms of MS 
involve a much more apparent steady reduction 
in one's functional ability (Barnwell & 
Kavanagh, 1997). 
A still not well understood disease, the 
causes of MS remain largely unknown. Scien-
tists point to several possible factors, including a 
genetic predisposition and environmental trig-
gers such as certain viruses, traumas, and heavy 
metals that likely contribute to the development 
of MS, though the strength of each contribution  
is not known (About MS). The average person 
has a 1 in 750 chance of developing MS, while 
someone who has a parent with the disease has a 
1 in 40 chance (About MS). Furthermore, twin 
studies have found that identical twins have a 1 
in 3 chance of developing MS if their co-twin 
has the disease. While this clearly points to a 
genetic component, it also suggests that environ-
mental factors make a difference. Otherwise, the 
chance would be much greater than 1 in 3 for 
two individuals with the same genetic make up 
(About MS). More than likely, there is an inter-
action effect, whereby one's genetic background 
makes an individual especially vulnerable to 
developing the disease, but whether or not the 
person actually develops the disease is dependent 
largely on environmental factors. 
A generally erratic, but progressively 
worsening illness, consisting either of alternating 
periods of stability and exacerbations or steady 
decline, multiple sclerosis takes a great toll on 
patients' mental health (Wingerson & Wineman, 
2000). Because of the day-to-day uncertainty the 
illness brings, and the fear of eventual physical 
incapacitation, many MS patients are also diag-
nosed with psychological illnesses, including 
most commonly depression (Shnek et al., 1997). 
MS patients also have increased rates of emo-
tional distress and are at increased risk for 
suicide (Wingerson & Wineman, 2000). With no 
cure likely to be found in the near future, medi-
cal treatments are still in their very beginning 
stages and focus mainly around reducing the 
severity of the symptoms and slowing the pro- 
gression of the disease. With treatments for MS 
only available since 1993, researchers have 
begun to explore psychological aspects of MS to 
determine whether attitudinal factors may affect 
the course of the disease, the severity of symp-
toms, and the mental health of MS patients 
(Fraser et al., 2001). 
Bandura's social cognitive theory stresses 
the importance of self-efficacy, an individual's 
confidence that he or she can perform a certain 
behavior or cope with a given situation, as a 
predictor of future performance. Bandura found 
that self-efficacy was a significant predictor of 
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not only successful performance, but also of 
amount of effort exerted and persistency in 
performance despite the presence of obstacles 
(Wassem, 1992). Thus, the psychological impact 
of self-efficacy is profound; high self-efficacy is 
often associated with positive outcome expecta-
tions and increased effort and persistence, and 
low self-efficacy, with poor outcome expecta-
tions and reduced effort (Wassem, 1992). This 
theory, which has been repeatedly supported by 
scientific findings, suggests that the strength of 
self-efficacy as a predictor is not limited to 
immediate effects, but that self-efficacy can also 
predict long-term outcome variables (Barnwell & 
Kavanagh, 1997). Thus, recent research on self-
efficacy has largely centered on exploring the 
strength of self-efficacy as a predictor of long-
term heath promoting behaviors and other 
important outcome. variables (Barnwell & 
Kavanagh, 1997). 
Self-efficacy, the belief that one has the 
ability to cope with a situation, has been found to 
have significant positive effects on coping, 
quality of life, and overall mental health (Riazi, 
Thompson, & Hobart, 2004). Research on other 
illnesses, specifically rheumatoid arthritis 
(Brekke, Hjortdahl, & Kvien, 2001, as cited in 
Riazi et al., 2004), sickle cell disease (Edwards, 
Telfair, Cecil, & Lenoci, 2001, as cited in Riazi 
et al., 2004), and fibromylagia (Buckelew et al., 
1996, as cited in Riazi et al., 2004), has found 
that improving self-efficacy has had positive 
effects on self-reported health status. Studies 
have also found a significant relationship be-
tween self-efficacy and other behavioral factors, 
such as assisting an individual's adjustment to 
the symptoms of their illness, improving adher-
ence to one's medical regimen, quitting smoking 
(Borrelli et al., 2002, as cited in Riazi et al., 
2004), reducing one's weight (McCann, 
Bovbjerg, Brief, & Turner, 1995, as cited in 
Riazi et al., 2004), and increasing one's adher-
ence to exercise programs (Pender, Bar-Or, Wilk, 
& Mitchell, 2002, as cited in Riazi et al., 2004) 
in individuals with diabetes, alcoholism, depres-
sion, cardiac disorders (Wassem, 1992), weight 
disorders (Fraser et al., 2001) and a host of other  
disorders (Barnwell & Kavanagh, 1997). There-
fore, the goal of this paper is to review research 
that looks at the relationship between self-
efficacy and health promoting behaviors, such as 
adherence to medical regimen and physical 
activity; symptom and overall illness severity; 
mental health status; and perceived quality of life 
in patients with multiple sclerosis. 
Review of the Literature 
The literature reviewed was found using 
Medline and Psyclnfo. This literature review is 
organized methodologically. The methodologi-
cal approaches of the 11 journal articles re-
viewed include two types of designs. One 
approach is correlational, and there are several 
types of correlational studies reviewed, including 
four cross-sectional studies, four longitudinal 
studies, and two retrospective studies. A second 
method is quasi-experimental, and one of the 
studies reviewed had a quasi-experimental 
design. 
Correlational Studies 
Ten correlational studies were reviewed. 
While different measures of self-efficacy were 
used in many of these studies, all data was 
obtained through the use of questionnaires. 
Cross-sectional Studies 
Four cross-sectional correlational studies 
assessed both self-efficacy and a number of 
outcome variables of interest, which varied 
among the studies. All of the variables were 
assessed through the use of questionnaires that 
were completed at a single point in time. 
Vercoulen et al. (1998) looked at the relationship 
between self-efficacy and fatigue, as well as 
other symptoms often comorbid with fatigue 
syndrome, in 50 Multiple Sclerosis patients. A 
diagnosis of MS was confirmed through a full 
physical and neurological examination con-
ducted prior to the onset of the study. Informa-
tion about self-efficacy was obtained through a 
single 5-point scale question, as well as through 
selected items from the Pain Cognition List 
believed to measure self-efficacy. Fatigue was 
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measured using the subjective fatigue subscale of efficacy and severity of illness. A significant 
the Checklist of Individual Strength. Other 	 negative relationship was also found between 
outcome measures included depression, which 	 self-efficacy and barriers. A significant positive 
was assessed using the Beck Depression Inven- 	 association was found between self-efficacy and 
tory, functional impairment, which was deter- 	 resources, acceptance of illness, health-promot- 
mined by the Sickness Impact Profile (SIP), 	 ing behaviors, and quality of life. All the above 
focus on bodily symptoms, which was measured mentioned relationships were assessed using a 
through the somatization subscale of the Symp- 	 significance level of .01. 
tom Checklist, and level of physical activity, 	 Wassem (1992) looked at the strength of 
which was assessed through the subscale of 	 self-efficacy as a predictor of adjustment to 
mobility on the SIP and through the Physical 	 disease in a convenience sample of 62 MS 
Activities Rating Scale. Vercoulen et al. (1998) 	 subjects. A diagnosis of multiple sclerosis was 
found, through structural equation modeling, a 	 determined based on demographic question- 
significant negative relationship between self- 	 naires, completed at clinic appointments and 
efficacy and fatigue. A significant positive 	 support group meetings of the National MS 
association was also found between self-efficacy Society, which included questions about an MS 
and level of physical activity. No significant 	 diagnosis. Self-efficacy was measured using the 
relationship was found between self-efficacy and Self-Efficacy for Adjustment Behaviors Scale, 
any of the other outcome variables. 	 which focused on three subscales of adjustment 
Stuifbergen et al. (2000) studied the 	 including psychosocial adjustment, self care 
relationship between self-efficacy and health 	 adjustment, and disease management adjustment. 
promoting behaviors, central to one's quality of 
	
Outcome variables included attitudes and behav- 
life, through questionnaires distributed to 786 
	
iors associated with one's adjustment to his or 
subjects with MS. A diagnosis of MS was 	 her disability, which was assessed using the 
assumed, on the basis that the sample was drawn integration subscale of the Bell Disability Scale 
from individuals, on the mailing list of the 	 of Adjustment, and level of disability, which was 
National MS Society chapters, who indicated a 	 measured using the Modified Disability Status 
diagnosis of multiple sclerosis. Self-efficacy 	 Scale. Wassem (1992) found self-efficacy to be 
was assessed through the Self-Rated Abilities for a significant predictor of adjustment, accounting 
Health Practices scale. Outcome variables 	 for 24% of the variance in adjustment. Most of 
examined in the study were chosen during a 	 this variance was accounted for by the psychoso-
preliminary phase of the study, when researchers cial subscale of the Self-Efficacy for Adjustment 
tried to identify key variables and antecedents 	 Behaviors Scale. Demographic variables, self-
highly related to health promoting behaviors and efficacy, and outcome expectations, combined, 
perceived quality of life in MS patients. Severity accounted for over half of the variance in adjust- 
of illness was assessed using the Incapacity 	 ment. Self-efficacy was not found to be a sig- 
Status Scale, barriers were assessed using the 	 nificant predictor of severity of illness. 
Barriers to Health Promoting Activities for 	 Shnek et al. (1997) considered the 
Disabled Persons Scale, resources were mea- 	 strength of self-efficacy as a predictor of depres- 
sured through the Personal Resource Question- 	 sion in 80 MS patients. A diagnosis of multiple 
naire, acceptance was assessed using the Accep- sclerosis was confirmed based on the diagnostic 
tance of Illness Scale, health-promoting behav- 	 criteria established by Pose et al. (1983), through 
iors were measured through the Health Promot- 	 a Medical Information Questionnaire, and also 
ing Lifestyle Profile-II, and quality of life was 	 through medical records. Questionnaires were 
measured by the Quality of Life Index. 	 used to gather data on predictive and outcome 
Stuifbergen et al. (2000) found a statistically 	 variables. Self-efficacy was measured using the 
significant negative relationship between self- 	 Beliefs Scale, a modified version of the Arthritis 
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Beliefs Scale. Depression was assessed through 
the Center for Epidemiologic Studies Depression 
Scale. Other variables included level of disabil-
ity, which was assessed using the Ambulation 
and Body Care and Movement Items Scale of the 
Sickness Impact Profile; learned helplessness, 
which was measured using the Attitudes Index; 
cognitive distortions, which was assessed 
through the Cognitive Beliefs Questionnaire; and 
other demographic and medical information, 
including status of employment, number of 
medications, and psychiatric disability which 
were established using the Medical Information 
Questionnaire. Shnek et al. (1997) found self-
efficacy to be a significant predictor of depres-
sion. Moreover, significant negative relation-
ships were identified between self-efficacy and 
cognitive distortions, and between self-efficacy 
and helplessness. There was no significant 
relationship between self-efficacy and employ-
ment, number of medications, psychiatric history, 
or disability. 
All of the cross-sectional correlational 
studies reviewed found a significant relationship 
between self-efficacy and at least one of the 
outcome variables of interest. Significant posi-
tive correlations were found between self-
efficacy and a number of outcome variables (e.g. 
physical activity, personal resources, acceptance 
of illness, health promoting behaviors, quality of 
life, and adjustment). Significant negative 
correlations were found between self-efficacy 
and a number of outcome variables (e.g. fatigue, 
barriers to health promoting activities, cognitive 
distortions, and helplessness). Ambiguous 
findings were reported as to a relationship 
between self-efficacy and severity of illness, and 
self-efficacy and depression. 
Longitudinal Studies 
Four of the studies were longitudinal 
correlational studies, and assessed both self-
efficacy and the outcome variables of interest, 
which vary among studies, through the use of 
questionnaires completed at two or more points 
in time. The follow-up time between the 
completion of pre- and post-measures ranged  
from six weeks to six months. 
Barnwell & Kavanagh (1997) were 
interested in the possible relationship between 
self-efficacy and psychological adjustment in 
multiple sclerosis patients. They looked at two 
aspects of self-efficacy; specifically, self-efficacy 
for social activity and self-efficacy for mood 
control. Seventy-one MS patients were initially 
assessed through questionnaires, if they had been 
obtained through a mailing list, or through an 
interview, if they had been found as subjects 
attending MS centers at the time of the study. 
Assessment at the two month follow-up was 
conducted via questionnaires. Self-efficacy for 
mood control was measured through the Self-
Efficacy  Questionnaire for Mood Control, and 
self-efficacy for social activity was assessed 
using the Self-Efficacy for Social Activity 
Questionnaire. Outcome measures for social 
activity and mood control were determined by 
looking at self-reported performance, also 
assessed through questionnaires. The outcome 
questionnaires consisted of lists of activities or 
events considered to be representative of social 
activity (P-Social) and mood control (P-Mood), 
and subjects were asked to place tick marks next 
to the activities or events they had participated in 
over the two month period. Other outcome 
measures included depression, assessed through 
the Beck Depression Inventory; self-esteem, 
measured using the Coopersmith Self-esteem 
Inventory; and severity of illness, determined by 
the physical dimension score of the Sickness 
Impact Profile. Barnwell & Kavanagh (1997) 
found self-efficacy for mood control to be a 
significant predictor of mood control and social 
activity, such that greater levels of self-efficacy 
were predictive of greater levels of mood control 
and higher amounts of social activity. Self-
efficacy for social activity was a significant 
predictor of mood control and social activity, that 
is greater levels of social activity self-efficacy at 
the baseline were associated with greater levels 
of mood control and social activity at the two 
month follow-up. Both types of self-efficacy 
were significant predictors of depression; high 
levels of self-efficacy were related to low levels 
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of depression at the two month follow-up. Both 
types of self-efficacy were also significant 
piedictors of self-esteem, such that greater levels 
of baseline self-efficacy were indicative of 
greater levels of self-esteem at follow-up. 
Lastly, both types of self-efficacy were signifi-
cant predictors of severity of illness at the fol-
low-up, such that greater levels of baseline self-
efficacy were indicative of lower levels of 
severity of illness at the follow-up. 
Riazi et al. (2004) studied the relation-
ship between self-efficacy and self-reported 
health status in 89 MS patients admitted to the 
National Hospital for Neurology and Neurosur-
gery for either rehabilitation treatment or intrave-
nous steroid treatment. Baseline levels of self-
efficacy were obtained upon hospital admission 
and at discharge for patients involved in rehabili-
tation treatment, or six weeks later for patients 
involved in intravenous steroid treatment. A 
diagnosis of multiple sclerosis was assumed due 
the admittance of the patients to the hospital for 
MS related treatment. Self-efficacy was assessed 
using the Multiple Sclerosis Self-Efficacy Scale, 
which includes two subscales that look specifi-
cally at functional ability and at confidence in 
functional abilities. The physical as well as the 
psychological impact of MS on a person, one's 
MS health status, was determined by the MS 
Impact Scale (MSIS-29). Walking, generally 
reflective of overall symptom severity, was 
measured using the Multiple Sclerosis Walking 
Scale. The inpatient rehabilitation treatment, 
which is highly individualized, is generally 
geared towards teaching problem-solving skills, 
promoting goal-oriented decision-making, and 
providing patients with overall techniques aimed 
at reducing the toll MS takes on daily living. 
Steroid treatment through the use of corticoster-
oids is used during MS relapses as a means of 
controlling the symptoms associated with an 
exacerbation and to prevent the relapse from 
getting progressively worse. 
Patients in the steroid group received lg 
of methylprednisolone every day for three con-
secutive days. Baseline measures revealed that 
patients who were part of the inpatient rehabilita- 
tion program were significantly more disabled 
than patients involved in the intravenous steroid 
treatment group. Riazi et al. (2004) found that, 
in both groups, greater self-efficacy scores were 
associated with better health status at both 
baseline and follow-up. It was also found that 
better initial functional self-efficacy scores and 
improvement in functional self-efficacy scores 
were significantly related to improvement on all 
outcome measures in both treatment groups. In 
the rehabilitation group, improvement in the 
control subscale of self-efficacy was a significant 
predictor of improvement in health status scores, 
as determined by the MSIS-29. In the steroid 
group, baseline functional self-efficacy scores 
were significant predictors of health status 
scores, as determined by the MSIS-29. Further-
more, baseline self-efficacy control scores and 
changes in functional self-efficacy and control 
self-efficacy were significant predictors of all 
outcome measures. 
In a sample of 101 patients with relaps-
ing-remitting multiple sclerosis, Mohr, 
Boudewyn, Likosky, Levine, & Goodkin (2001) 
studied the relationship between self-efficacy 
and adherence to Interferon beta-la medication, 
a drug treatment that must be injected weekly, 
and that is aimed at slowing the progression of 
multiple sclerosis and reducing the number and 
intensity of exacerbations. Patients were se-
lected from those MS patients approved to begin 
this type of drug therapy, and were excluded if 
they had had prior experience with self-injection, 
since researchers were partly interested in 
whether high injection anxiety would lead to 
lower adherence. Patients' self-efficacy, injec-
tion anxiety, and adherence expectations were 
assessed through questionnaires read to partici- 
pants during telephone interviews two weeks 
prior to the start of treatment, two weeks after 
the onset of treatment, and at an eight week 
follow-up. Self-efficacy was assessed using the 
Injection Self-Efficacy Expectations Scale. 
Other variables included injection anxiety, which 
was measured through the Injection Anxiety 
Expectations Scale; adherence expectations, 
which were determined through the Adherence 
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Expectation Rating Scale; and illness severity, 
which was assessed through the Guy's Neuro-
logical Disability Scale. Adherence was mea-
sured at the six month follow-up through patient 
self-report and through confirmation from the 
KPMC pharmacy that the patient was or was not 
having their prescription refilled. 
Mohr et al. (2001) found a significant 
negative association between pre-treatment self-
efficacy and pre-treatment anxiety. Injection 
self-efficacy determined at the eight-week 
follow-up was significantly related to post-
treatment experienced injection anxiety, such 
that the greater one's self-efficacy about the 
ability to self-inject, the less self injection anxi-
ety experienced. Injection self-efficacy was 
found to be significantly related to Interferon 
beta-la adherence at six months; however, this 
relationship was found to be fully mediated by 
the identity of the injection administrator (i.e. the 
patient, the spouse, the health provider, etc.) 
Thus, the relationship that exists between self-
efficacy and adherence is not sufficient by itself, 
but rather is completely dependent on the injec-
tion administrator. 
Fraser, Morgante, Hadjimichael, & 
Vollmer (2004) looked at self-efficacy as a 
possible predictor of adherence to Glatiramer 
Acetate (Copaxone) intravenous medication in a 
convenience sample of 108 MS patients who had 
already initiated therapy with Copaxone. Self-
efficacy and other psychological variables were 
assessed prior to beginning drug therapy, and 
adherence was assessed at a six month follow-
up. Self-efficacy was measured using the Mul-
tiple Sclerosis Self-Efficacy Scale (MSSE). 
Adherence was defined, by self-report, as con-
tinuing therapy with Copaxone subcutaneously, 
daily for at least six months. Fraser et al. (2004) 
found self-efficacy to be a significant predictor 
of adherence to Copaxone therapy, and the 
adherent group had significantly higher self-
efficacy scores than the non-adherent group. 
Initial self-efficacy scores accurately predicted 
adherence to Copaxone therapy at the six month 
follow-up for 98.8% of those in the adherent 
group. 
Of the longitudinal correlational studies 
reviewed, all four found a significant relation-
ship between self-efficacy and at least one of the 
outcome variables of interest. Significant posi-
tive correlations were found between self-
efficacy and a number of desirable outcome 
variables (e.g., mood control, social activity, self-
esteem, health status, and adherence). Signifi-
cant negative correlations were found between 
self-efficacy and a number of adverse outcome 
variables (e.g., depression, severity of illness, 
and pre-treatment anxiety). 
Retrospective Studies 
Two of the studies reviewed were retro-
spective correlational studies. In both of these 
studies, self-efficacy was assessed using the 
Multiple Sclerosis Self-Efficacy Scale (MSSE) 
in the present, and subjects were asked to recon-
struct levels of adherence over the past year. 
Fraser et al. (2001) were interested in the rela-
tionship between self-efficacy and adherence to 
Copaxone therapy in 341 patients with relapsing-
remitting MS. Subjects included those who had 
been adherent to Copaxone therapy for at least 
the prior year (n=225), and those non-adherent to 
Copaxone therapy during the prior year (n=116). 
Researchers believed that self-efficacy scores 
taken at the time of the study would be able to 
correctly classify individuals as to whether they 
had been adherent to Copaxone therapy during 
the prior year. Adherence was defined as con-
tinuing therapy with Copaxone daily for at least 
one year. Fraser et al. (2001) found the control 
subscale of the self-efficacy measure to be a 
significant predictor of adherence. The higher 
one's score on the control subscale of the MSSE, 
the more likely that individual was to have 
adhered. The adherent group had significantly 
greater self-efficacy that they could control their 
MS. Functional self-efficacy, one's confidence 
in his or her ability to function despite MS, was 
not a significant predictor of adherence. 
Fraser, Hadjimichael, & Vollmer (2003) 
studied the strength of self-efficacy as a predictor 
of adherence to Copaxone therapy in 199 sub-
jects with progressive MS. Subjects included 
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those who had been adherent and had taken 
Copaxone for at least one year (n=107), and 
those non-adherent who had discontinued 
therapy before the end of the year (n=92). There-
fore, researchers were interested in whether self-
efficacy measures, obtained at the time of the 
study, could properly classify individuals as to 
whether they had adhered or not adhered to 
Copaxone therapy during the prior year. Fraser 
et al. (2003) found both subscales of self-effi-
cacy, the control subscale and the function 
subscale, to be significant predictors of adher-
ence. The greater one's score on the MSSE, the 
more likely that individual was to have adhered. 
Both retrospective correlational studies reviewed 
found a significant positive relationship between 
self-efficacy and adherence to Copaxone therapy. 
Quasi-experimental Studies 
One of the studies was a within-subjects 
(pre-post) quasi-experimental study. In this 
study, random assignment was not used, and 
thus, the study must be considered a quasi-
experimental study, since true experimental 
designs require random assignment. The fact 
that all subjects were assigned to the intervention 
makes this study a within-subjects design. 
Wingerson & Wineman (2000) considered the 
relationship between self-efficacy and overall 
mental health during a community-based treat-
ment involving a convenience sample of 12 
subjects with MS who indicated a need for 
counseling. All subjects participated in the 
short-term counseling intervention, which 
consisted of individualized therapy based on the 
person's particular needs. Self-efficacy was 
measured prior to the beginning of the interven-
tion and at the conclusion of the intervention, 
using a modified version of the Self-Efficacy 
Instrument. The outcome variable mental health 
was assessed through the Mental Health Inven-
tory. All measures were assessed at pre-treat-
ment and at post-treatment, and pre-treatment 
measures were used to formulate individual 
treatment plans. Wingerson & Wineman (2000) 
found a significant improvement in self-efficacy 
when comparing pre and post self-efficacy  
scores. However, there was no significant 
improvement in mental health as a result of 
treatment. Hence, the only quasi-experimental 
study reviewed found no relationship between 
self-efficacy and mental health. 
Discussion 
Summary of Findings 
' 	 Of the 11 studies reviewed, almost all 
report a statistically significant relationship 
between self-efficacy and at least one of the 
outcome variables tested. However, there is still 
some disparity over which variables can be 
significantly predicted by self-efficacy, because 
while some studies report a significant relation-
ship with a specific outcome variable, other 
studies fail to detect this relationship. All six 
studies that looked at the relationship between 
self-efficacy and health promoting behaviors 
such as level of physical activity, level of social 
activity, and adherence to medical regimens, and 
related feelings about health promoting behav-
iors (such as perceived barriers to health promot-
ing behaviors and belief in availability of re-
sources), found significant relationships. While 
most of these studies looked at the health pro-
moting variable of adherence to MS medication, 
and relatively few considered other health pro-
moting behaviors, all four studies that considered 
adherence found a statistically significant rela-
tionship between self-efficacy and treatment 
adherence. Furthermore, adherence was assessed 
in these studies over a relatively long period of 
time, ranging from six months to one year, 
lending them fairly good credibility. Generally, 
the longer the follow-up period, the greater the 
strength of the findings. Studies that have longer 
follow-up periods are more likely to detect true 
effects as opposed to chance findings or short-
lived relationships that may be present immedi-
ately following an intervention. Because of this, 
studies that use longer follow-ups are generally 
accepted as methodologically stronger than those 
studies that have relatively short follow-ups. 
These findings suggest that it may be beneficial 
for treatment centers to consider a person's self-
efficacy before starting him or her on intrave- 
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nous MS medications, because people with low 
self-efficacy may not benefit from this treatment 
without further intervention to improve their 
level of self-efficacy. The remaining studies, 
focusing on the relationship between self-effi-
cacy and health promoting behaviors, considered 
different outcome variables, and thus were 
unable to replicate findings and establish proof 
of a real relationship. However, because all 
relationships considered between self-efficacy 
and health promoting behaviors were found to be 
significant, it is likely that self-efficacy is related 
to health promoting behaviors, and that self-
efficacy may serve as a predictor of adherence, 
level of physical activity, and other health pro-
moting activities. 
Of the six studies that considered the 
relationship between self-efficacy and physical 
symptom severity, functional impairment, fa-
tigue, health status, and overall illness severity, 
three found significant relationships, two did not 
find a statistically significant relationship, and 
one had somewhat inconsistent results, finding a 
significant relationship between one of the 
health-related variables and self-efficacy, but 
failing to find a significant relationship between 
self-efficacy and the other health-related vari-
able. Ultimately, most of the discrepancy had to 
do with the relationship between self-efficacy 
and illness severity, with two studies finding a 
significant relationship and one not. While 
clearly the association between self-efficacy and 
health status is questionable based on this re-
view, these results may be attributable to the way 
in which health status was measured. For ex-
ample, studies that provided purely physical 
assessments of health status, such as functional 
impairment or extent of disability—excluding 
more subjective symptoms such as fatigue—
generally did not find a statistically significant 
relationship with self-efficacy. However, studies 
that employed a more subjective measure of 
disability (e.g., perceived illness severity or 
perceived health status) often did find a signifi-
cant relationship with self-efficacy. This sug-
gests that self-efficacy may influence people's 
subjective assessments of their overall health  
status, and that those with greater self-efficacy 
may downplay the negative aspects of their 
illness and exercise the sense of control they 
believe they have over its severity. However, 
when these same subjects are asked to objec-
tively report the severity of specific physical 
symptoms of their disease, such as the extent of 
their disability or the actual impairment they 
face, self-efficacy may not be related to their 
actual physical state. In other words, perceived 
self-efficacy may be significantly related to 
variables such as perceived severity of illness 
because having self-efficacy allows people to 
look past the specific physical problems they 
may encounter and still maintain a positive sense 
of control over the extent of their disability. At 
the same time, self-efficacy may not be related to 
symptom severity or severity of impairment 
because, while self-efficacy may give people a 
more positive attitude, it does not allow them to 
overlook specific physical shortcomings. This is 
not surprising, given the fact that self-efficacy is 
fundamentally defined in terms of self-percep-
tion. Thus, outcome variables which depend, in 
large part, on perception may be more strongly 
related to self-efficacy than more objective 
variables. 
Out of four studies that looked at the 
relationship between self-efficacy and psycho-
logical outcomes, including mental health status, 
feelings of helplessness, cognitive distortions, 
depression, mood control, and self-esteem, half 
found a significant relationship and half did not. 
Most of the inconsistency had to do with the 
relationship between self-efficacy and depres-
sion; two studies found a significant relationship 
and one did not. Due to this inconsistency, 
further research must be done before a relation-
ship can be established between self-efficacy and 
depression. However, studies that focused on the 
relationship between self-efficacy and other 
psychological components did find a significant 
relationship with cognitive distortions, feelings 
of helplessness, mood control, and self-esteem, 
suggesting that self-efficacy may be associated 
with other cognitive components. It is reason-
able to assume that self-efficacy, defined as the 
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belief of control one feels over one's MS, may 
impact other cognitive aspects such as feelings 
of helplessness and self-esteem, because these 
psychological components are also largely 
affected by self-perception. People with greater 
self-efficacy, who feel strength in their ability to 
control their MS and their future, likely perceive 
themselves in a better light and probably have 
fewer feelings of helplessness and greater self-
esteem than individuals with low self-efficacy. 
However, because these relationships were not 
repeatedly tested and their findings replicated, 
one cannot be certain as to whether a true rela-
tionship exists. 
Lastly, of the two studies that looked at 
perceived quality of life, including acceptance of 
illness and overall adjustment to illness, both 
found statistically significant relationships. 
Clearly, it is conceivable that individuals with 
greater self-efficacy would report a greater 
perceived quality of life and likely consider 
themselves to be more adjusted and more accept-
ing of their illness than those with low self-
efficacy. However, one must hesitate before 
drawing this conclusion based on the limited 
amount of research that has been done in this 
area. Further research is necessary before a 
relationship between self-efficacy and perceived 
quality of life can be deemed credible, and 
replication is vital before a relationship between 
self-efficacy and the above mentioned variables 
can be confirmed. 
Strengths of the Literature Reviewed 
There are several strengths to the litera-
ture reviewed in this paper. Almost all of the 
correlational studies had moderate to large 
sample sizes. Furthermore, of these studies, 
those that performed an analysis of the demo-
graphic characteristics of their sample found 
their sample to be a fairly accurate representation 
of the MS population-samples were largely made 
up of white, middle-age women. Having a 
moderate to large sample size increases the 
likelihood of also having a representative 
sample, and a representative sample allows one 
to generalize findings to the greater population  
with more confidence. 
Another strength of the literature re-
viewed in this paper is that, methodologically, 
many of the variables of interest were assessed 
using instruments demonstrated to be internally 
consistent. For example, four of the studies used 
the Multiple Sclerosis Self-Efficacy Scale 
(MSSE) as a measure of self-efficacy, a scale 
developed specifically to measure self-efficacy in 
MS patients, with a recognized overall alpha of 
around .89 (Schwartz, Coulthard-Morris, Zeng, 
& Retzlaff, 1996, as cited in Fraser et al., 2003 ). 
Shnek et al. (1997) also report an alpha of .89 for 
the Beliefs Scale, used to assess self-efficacy in 
their study. Wassem (1992) reports Cronbach's 
alpha for the Self-Efficacy for Adjustment 
Behaviors Scale to be .91. Barnwell & 
Kavanagh (1997) report the internal consistency 
of the two subscales of their self-efficacy mea-
sures, self-efficacy for mood control and self-
efficacy for social activity, to be .91 and .90, 
respectively. Furthermore, in all but two of the 
studies reviewed, researchers report the self-
efficacy scale used to have been previously 
proven valid and reliable. In Wingerson & 
Wineman (2000) test-retest reliability for the 
Self-Efficacy Instrument is reported to be be-
tween. .82 and .89, and construct validity be-
tween .14 to .68. It is important that the instru-
ments used are internally consistent, as well as 
valid and reliable, because if they are not, then 
one cannot be completely confident in the find-
ings, even if they are statistically significant. 
Weaknesses of the Literature Reviewed 
Unfortunately, there are many shortcom-
ings to the literature reviewed. Methodologi-
cally, there were no true experiments conducted 
to test the relationship between self-efficacy and 
any of the outcome variables of interest. This 
means that a cause and effect relationship cannot 
be established. Furthermore, there was only one 
quasi-experimental study, and that study was 
quite weak, with an extremely small sample size 
and no control group. While quasi-experimental 
studies are inherently weak due to their lack of 
random assignment, often this weakness can be 
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offset, at least in part, by the presence of a 
control group, which can be compared to the 
experimental group in order to determine 
whether a cause and effect relationship is likely. 
However, the quasi-experimental study reviewed 
did not have a control group, which means that 
one cannot be certain that the findings were a 
result of a change in self-efficacy and indicative 
of a true cause-and-effect relationship, or 
whether the results were attributable to some 
specific factor associated with the treatment. In 
order to eliminate this possibility, one must 
always include a control group. 
The lack of experimental studies also 
makes it difficult to identify a cause-and-effect 
relationship because confounds cannot be con-
trolled. For example, one health promoting 
behavior tends to be associated with other health 
promoting behaviors. That is, an individual who 
partakes in a health promoting behavior (e.g., 
exercising), is likely to also partake in other, 
related health promoting behaviors (e.g., healthy 
diet or not smoking). Because of this, it is 
almost impossible to determine, based strictly on 
a significant correlational relationship, whether a 
finding is indicative of a cause-and-effect rela-
tionship, a by-product of an outcome variable, or 
a result of other related outcome variables. In 
other words, if a statistically significant relation-
ship was detected between self-efficacy and 
exercising, this finding may be reflective of a 
true cause-and-effect relationship, whereby one 
of the variables causes changes in the other 
variable. However, it may also be the case that 
the finding is attributable to a relationship 
between self-efficacy and a by-product of exer-
cise (e.g., increased self-esteem). 
Because all but one of the studies re-
viewed were correlational in nature, it is impos-
sible to determine with certainty whether a true 
relationship exists, or whether the observed 
association is a result of each variables' relation-
ship with a third variable. For example, in terms 
of the presumed relationship between self-
efficacy and health promoting behaviors, it could 
be that the relationship between self-efficacy and 
health promoting behaviors is determined by a  
third variable, such as illness severity, or by 
another psychological component such as opti-
mism. If self-efficacy and illness severity are 
highly correlated, and illness severity and health 
promoting behaviors are highly correlated, then, 
while it may appear statistically that self-efficacy 
and health promoting behaviors are highly 
correlated, this may not be indicative of an 
underlying cause-and-effect relationship at all. 
Instead, illness severity may be affecting both 
self-efficacy and health promoting behaviors—
with greater illness severity resulting in lower 
levels of self-efficacy and lower levels of health 
promoting behaviors. Thus, each variable's 
relationship to illness severity might create the 
appearance of a cause-and-effect relationship, 
when in reality no such relationship exists. 
Another problem with this heavy reliance 
on correlational studies, especially cross-sec-
tional studies, is that they cannot determine with 
confidence the direction of a relationship. For 
example, in considering the findings of 
Vercoulen et al. (1998), one can speculate that 
higher self-efficacy causes people to partake in 
greater amounts of physical activity. However, it 
could be the case that partaking in greater 
amounts of physical activity causes people to 
have greater strength in their belief that they can 
control their MS. When data are obtained at 
only one point in time, as they are with cross-
sectional studies, it is almost impossible to 
determine directionality with a high degree of 
confidence. 
Another weakness is that none of the 
studies reviewed were prospective studies. This 
means that the effects of self-efficacy on MS can 
only be looked at after the disease has mani-
fested itself and a diagnosis has been made. 
Whether a higher or lower level of self-efficacy 
has an effect on the onset of MS, or on factors 
that lead to the development of multiple sclerosis 
cannot be determined. 
Only three of the correlational studies 
reviewed included follow-ups, and the follow-up 
periods were relatively short, ranging from two 
to six months. Clearly, longitudinal studies are 
methodologically stronger than cross-sectional 
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and retrospective studies, because there is a 
greater likelihood that true effects will be de-
tected, as opposed to temporary effects or chance 
findings. When trying to determine whether self-
efficacy has an effect on the physical symptoms 
of MS, longitudinal studies are much preferred. 
If the effects of self-efficacy were present only 
for a short time period following a treatment, 
cross-sectional studies or longitudinal studies, 
where the follow-up time is minimal, would 
misinterpret the effects of self-efficacy as long-
lasting, when in fact they may be temporary. 
Further, if the effects of self-efficacy were 
delayed, even longitudinal studies may not detect 
this relationship if the follow-up periods are 
short. Especially in terms of physical symptoma-
tology, whether findings are considered signifi-
cant is determined largely by the degrees of 
protective effects offered and the lengths of time 
that the protective effects last. Thus, in order for 
self-efficacy to be viewed as a valuable tool for 
reducing the impact of symptoms or lessening 
overall illness severity, the long-term effects of 
self-efficacy would have to be demonstrated. In 
order to accomplish this, it would be necessary 
to follow a group of MS patients for several 
years, in order to see whether levels of self-
efficacy could predict exacerbations of MS. 
Suggestions for Future Research 
Taking into consideration the several 
strengths and the numerous flaws of the re-
viewed literature, an ideal study looking at the 
relationship between self-efficacy and health 
promoting behaviors, physical symptoms and 
illness severity, mental health, and quality of life 
would include an experimental design with a 
long-term follow-up. Ideally, one might want to 
use a prospective design. However, because so 
little is known about the cause of MS, many 
resources may be wasted using this design on 
large groups of individuals who might never 
develop MS. A more productive study would 
consist of an experimental between-subjects 
design, that includes a large group (n=500) of 
MS patients. Pre-test measures would be ob-
tained through the use of questionnaires on self- 
efficacy, health promoting behaviors, mental 
health, physical symptomatology, and perceived 
quality of life, and then patients would be ran-
domly assigned to either a treatment condition or 
a control condition. If a large sample could not 
be obtained, then surely subjects would need to 
be matched on important disease characteristics, 
such as extent of disability. The treatment 
condition would involve self-efficacy training, 
and following the intervention, post-test mea-
sures would be obtained. While multi-modal 
treatments that involve stress management 
training or teaching coping skills may be consid-
ered more effective overall, using this type of 
treatment approach to address the question at 
hand would not be desirable. Using a multi-
modal treatment approach, where the treatment 
is multi-faceted, causes later ambiguity because 
it is difficult to distinguish between and deter-
mine the effectiveness of different components 
of the treatment, as it is also difficult to deter-
mine whether the observed results were the 
result of an interaction between some of the 
treatments and not others. Thus, multi-modal 
treatments complicate matters when trying to 
establish a causal relationship and identify a 
relationship between self-efficacy and the vari-
ables in question. Furthermore, including a 
long-term follow-up, perhaps testing subjects on 
all measures every six months for ten years, 
would provide a much more accurate picture of 
the relationship between self-efficacy and out-
come variables such as health promoting behav-
iors, symptom and overall illness severity, 
mental health status, and perceived quality of life 
in MS patients, and also provide a better under-
standing about the strength of these relation-
ships. Also, using a long-term follow-up would 
allow for a better look into the possible relation-
ship between self-efficacy and symptom severity, 
because it is likely that subjects would experi-
ence exacerbations during a longer time period, 
and self-efficacy could be assessed in relation to 
these symptomatic relapses. 
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